78.62

0.99% 0.77

After Hours: 77.50 -1.12 -1.42%

Protagonist Therapeutics Inc (PTGX)

Overview News Price History Option Chain Financials Why PTGX Down? Discussions Forecast

Protagonist Therapeutics Inc stock is traded at $78.62, with a volume of 723.14K. It is up +0.99% in the last 24 hours and up +18.35% over the past month. Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Previous Close:

$77.85

Open:

$77.53

24h Volume:

723.14K

Relative Volume:

0.66

Market Cap:

$4.89B

Revenue:

$209.18M

Net Income/Loss:

$52.04M

P/E Ratio:

110.34

EPS:

0.7125

Net Cash Flow:

$37.10M

1W Performance:

+5.02%

1M Performance:

+18.35%

6M Performance:

+71.58%

1Y Performance:

+71.51%

1-Day Range:

$76.66

$79.01

1-Week Range:

$74.03

$79.01

52-Week Range:

$33.31

$93.25

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name

Protagonist Therapeutics Inc

Sector

Healthcare (1135)

Industry

Biotechnology (635)

Phone

(510) 474-0170

Address

7707 GATEWAY BLVD., SUITE 140, NEWARK, CA

Employee

130

Twitter

Next Earnings Date

2025-05-02

Latest SEC Filings

PTGX's Discussions on Twitter

Compare PTGX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PTGX Protagonist Therapeutics Inc	78.62	4.84B	209.18M	52.04M	37.10M	0.7125
VRTX Vertex Pharmaceuticals Inc	425.57	107.66B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	651.80	68.74B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	456.04	58.93B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	818.50	50.51B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	189.60	41.29B	447.02M	-1.18B	-868.57M	-6.1812

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-17-25	Initiated	Barclays	Overweight
Sep-12-25	Initiated	Leerink Partners	Outperform
Jun-17-25	Initiated	Citigroup	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Dec-06-24	Initiated	Goldman	Neutral
Nov-05-24	Initiated	Wedbush	Outperform
Sep-24-24	Initiated	TD Cowen	Buy
Sep-09-24	Initiated	Truist	Buy
Oct-30-23	Initiated	CapitalOne	Overweight
May-25-23	Resumed	Jefferies	Buy
Aug-25-22	Initiated	JMP Securities	Mkt Outperform
Feb-11-22	Initiated	BTIG Research	Buy
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral
May-24-21	Initiated	JMP Securities	Mkt Outperform
May-24-21	Initiated	Northland Capital	Outperform
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight
Sep-18-20	Reiterated	H.C. Wainwright	Buy
Jul-15-20	Initiated	Jefferies	Buy
May-18-20	Reiterated	H.C. Wainwright	Buy
Jul-08-19	Initiated	H.C. Wainwright	Buy
May-09-19	Upgrade	Stifel	Hold → Buy
Dec-06-18	Initiated	Nomura	Buy
Jan-29-18	Initiated	Stifel	Buy
Jul-21-17	Initiated	BTIG Research	Buy

View All

Protagonist Therapeutics Inc Stock (PTGX) Latest News

02:21 AM

Leerink Partnrs Issues Optimistic Forecast for PTGX Earnings - MarketBeat

02:21 AM

12:23 PM

Is Protagonist Therapeutics Inc. stock entering bullish territoryWeekly Market Outlook & Accurate Intraday Trade Tips - newser.com

12:23 PM

Nov 02, 2025

Can Protagonist Therapeutics Inc. hit a new high this month2025 Earnings Impact & Short-Term High Return Ideas - newser.com

Nov 02, 2025

How strong is Protagonist Therapeutics Inc. stock revenue growth2025 Momentum Check & Safe Capital Preservation Plans - newser.com

Nov 02, 2025

Price action breakdown for Protagonist Therapeutics Inc.July 2025 Recap & Free Fast Gain Swing Trade Alerts - newser.com

Nov 02, 2025

Nov 01, 2025

Is Protagonist Therapeutics Inc. stock a top pick in earnings season2025 Momentum Check & Weekly Return Optimization Alerts - newser.com

Nov 01, 2025